Quince Therapeutics (QNCX) Return on Capital Employed (2019 - 2026)
Quince Therapeutics (QNCX) posted quarterly Return on Capital Employed of 112.66% for Q1 2026, down 5318.0% year-over-year from 2.16% in Q1 2025, and down 13.47% quarter-over-quarter from 99.29% in Q4 2025.
Quince Therapeutics (QNCX) Return on Capital Employed (2019 - 2026) Analysis & Trends
Quince Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 112.66% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 5318.0% year-over-year to 112.66%; the TTM figure through Mar 2026 stood at 112.66% (down 5318.0% YoY), while the FY2025 annual figure was 95.55%, down 5277.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 112.66%, down from 99.29% in the prior quarter.
- The five-year high for Return on Capital Employed was 21.34% in Q1 2024, with the low at 112.66% in Q1 2026.
- The 5-year median for Return on Capital Employed is 50.17% (2022), against an average of 55.35%.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed surged 3861 bps in 2023, then slumped 5318 bps in 2026.
- Quince Therapeutics' Return on Capital Employed stood at 50.17% in 2022, then soared by 41 bps to 29.52% in 2023, then sank by 71 bps to 50.6% in 2024, then plunged by 96 bps to 99.29% in 2025, then retreated by 13 bps to 112.66% in 2026.
- Business Quant data shows QNCX's Return on Capital Employed at 112.66% in Q1 2026, 99.29% in Q4 2025, and 57.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | -190.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112.66% |
| Dec 31, 2025 | -99.29% |
| Sep 30, 2025 | -57.97% |
| Jun 30, 2025 | -41.23% |
| Mar 31, 2025 | -59.48% |
| Dec 31, 2024 | -50.60% |
| Sep 30, 2024 | -44.07% |
| Jun 30, 2024 | -40.53% |
| Mar 31, 2024 | -21.34% |
| Dec 31, 2023 | -29.52% |
| Sep 30, 2023 | -36.48% |
| Jun 30, 2023 | -36.44% |
| Mar 31, 2023 | -45.19% |
| Dec 31, 2022 | -50.17% |
| Sep 30, 2022 | -63.64% |
| Jun 30, 2022 | -75.05% |
| Mar 31, 2022 | -77.30% |
| Dec 31, 2021 | -71.62% |
| Sep 30, 2021 | -62.48% |
| Jun 30, 2021 | -58.80% |